Jun 2026 (Q2 FY26) — Jul 31, 2026
AbbVie Q2 FY26 — Strong Growth Across Key Products and Strategic Acquisition
Read the full callAbbVie (ABBV) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
AbbVie earnings: last reported Fri, 31 Jul 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 16,990 | +10.2% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 37.9 | +6.1 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 3,613 | +285.2% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Guidance
What management said, and what became of it
27 of 46 judged targets kept · 58 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Net revenues | approximately $16.7 billion | Mar 2026 | Total net revenues were nearly $17 billion, beating our expectations by $300 million and reflecting robust sales growth of 10.2%. | Achieved |
| Adjusted EPS | $3.74 - $3.78 | Mar 2026 | We achieved adjusted earnings per share of $3.65, which is $0.06 above our guidance midpoint. | Missed |
| Adjusted EPS | $14.37 - $14.57 | Dec 2025 | we are updating our full year adjusted earnings per share guidance to between $13.87 and $14.07. | Revised Down |
19 of AbbVie Inc.'s 104 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 101 more targets are in the full ledger.
Claimed
- Adjusted EPS of $3.65, exceeding guidance midpoint by $0.06.
- Total net revenues of nearly $17 billion, beating expectations by $300 million, reflecting 10.2% robust sales growth.
- Skyrizi, Rinvoq, and neuroscience portfolio delivered double-digit sales growth, each above 20%.
- Full-year revenue guidance raised by $300 million, totaling $600 million increase since year start.
- Acquisition of Apogee Therapeutics bolsters immunology pipeline with significant sales potential.
Qualified
- Humira global sales down 36.1% operationally due to biosimilar competition, in line with expectations.
- IMBRUVICA sales down 29.4% due to IRA pricing and competitive share pressure.
- Juvederm global sales down 6.6% operationally, reflecting continued headwinds in key dermal filler markets.
- Full-year adjusted EPS guidance updated to $13.87-$14.07, reflecting $0.14 dilution from Apogee acquisition.
- Adjusted net interest expense increased by $200 million to $2.9 billion due to Apogee financing costs.
Price
$282.78 −0.92% · −$2.64
Performance +23.2% 1Y
1Y: $229.57 on 17 Oct 2025 → $282.78. High $285.42 (16 Oct 2026), low $197.38 (27 Apr 2026).
- Previous close
- $285.42
- 52-week range
- $197.38 – $285.42
- One year
- +21.86%
Overview
- Symbol
- ABBV
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Guidance
What management said, and what became of it
27 of 46 judged targets kept · 58 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Net revenues | approximately $16.7 billion | Mar 2026 | Total net revenues were nearly $17 billion, beating our expectations by $300 million and reflecting robust sales growth of 10.2%. | Achieved |
| Adjusted EPS | $3.74 - $3.78 | Mar 2026 | We achieved adjusted earnings per share of $3.65, which is $0.06 above our guidance midpoint. | Missed |
| Adjusted EPS | $14.37 - $14.57 | Dec 2025 | we are updating our full year adjusted earnings per share guidance to between $13.87 and $14.07. | Revised Down |
Claimed
- Adjusted EPS of $3.65, exceeding guidance midpoint by $0.06.
- Total net revenues of nearly $17 billion, beating expectations by $300 million, reflecting 10.2% robust sales growth.
- Skyrizi, Rinvoq, and neuroscience portfolio delivered double-digit sales growth, each above 20%.
- Full-year revenue guidance raised by $300 million, totaling $600 million increase since year start.
- Acquisition of Apogee Therapeutics bolsters immunology pipeline with significant sales potential.
Qualified
- Humira global sales down 36.1% operationally due to biosimilar competition, in line with expectations.
- IMBRUVICA sales down 29.4% due to IRA pricing and competitive share pressure.
- Juvederm global sales down 6.6% operationally, reflecting continued headwinds in key dermal filler markets.
- Full-year adjusted EPS guidance updated to $13.87-$14.07, reflecting $0.14 dilution from Apogee acquisition.
- Adjusted net interest expense increased by $200 million to $2.9 billion due to Apogee financing costs.
The full ledger
Open AbbVie Inc.’s full ledger
A free account opens 5 company ledgers a month. All 104 tracked commitments, with each call’s wording and source.
Call summaries
Mar 2026 (Q1 FY26) — Apr 29, 2026
AbbVie Q1 FY26 — Skyrizi/Rinvoq momentum drives beat and raised FY EPS guide
Read the full callDec 2025 (Q4 FY25) — Feb 4, 2026
AbbVie Q4 FY25 — Strong Immunology and Neuroscience Drive Record Sales and Exceed Guidance
Read the full callEvery analysed call
AbbVie earnings calls (ABBV)
Financials
What the filings say
Net profit, year on year: +285% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 14,460 | 15,102 | 13,343 | 15,423 | 15,776 | 16,618 | 15,002 | 16,990 |
| Expenses | 10,629 | 16,592 | 9,610 | 10,529 | 13,872 | 12,074 | 11,012 | 10,558 |
| Operating profit | 3,831 | -1,490 | 3,733 | 4,894 | 1,904 | 4,544 | 3,990 | 6,432 |
| Operating margin | 26.5% | −9.9% | 28.0% | 31.7% | 12.1% | 27.3% | 26.6% | 37.9% |
| Interest | 720 | 702 | 700 | 740 | 739 | 714 | 717 | 746 |
| Profit before tax | 2,084 | -2,269 | 1,661 | 1,554 | 714 | 2,668 | 1,039 | 4,278 |
| Tax rate | 24.9% | 99.0% | 22.4% | 39.5% | 73.7% | 32.0% | 32.9% | 15.5% |
| Net profit | 1,561 | -22 | 1,286 | 938 | 186 | 1,816 | 695 | 3,613 |
| EPS ($ per share) | 0.88 | -0.02 | 0.72 | 0.52 | 0.10 | 1.02 | 0.39 | 2.04 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Reserves | 3,368 | 4,717 | 1,055 | 3,127 | 4,784 | -1,000 | -7,900 | -15,493 |
| Total liabilities | 67,798 | 97,287 | 137,468 | 131,093 | 121,518 | 124,314 | 131,797 | 137,188 |
| Fixed assets | 2,883 | 2,962 | 5,248 | 5,110 | 4,935 | 4,989 | 5,134 | 5,628 |
| Investments | 772 | 0 | 30 | 84 | 28 | 2 | 31 | 28 |
| Total assets | 59,352 | 89,115 | 150,565 | 146,529 | 138,805 | 134,711 | 135,161 | 133,960 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 13,427 | 13,324 | 17,588 | 22,777 | 24,943 | 22,839 | 18,806 | 19,030 |
| Cash from investing | -1,006 | 596 | -37,557 | -2,344 | -623 | -2,009 | -20,820 | -6,643 |
| Cash from financing | -14,396 | 18,708 | -11,501 | -19,039 | -24,803 | -17,222 | -5,211 | -12,724 |
| Net cash flow | -2,014 | 32,635 | -31,475 | 1,297 | -545 | 3,613 | -7,290 | -295 |
| Capital expenditure | -638 | -552 | -798 | -787 | -695 | -777 | -974 | -1,214 |
| Free cash flow | 12,789 | 12,772 | 16,790 | 21,990 | 24,248 | 22,062 | 17,832 | 17,816 |
ABBV revenue by segment
| Segment | Q3 FY2024 | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|---|---|
| SKYRIZI | 44% | 50% | 51% | 57% | 60% | 60% | 60% | 65% | +24.5% |
| RINVOQ | 22% | 24% | 26% | 26% | 28% | 29% | 28% | 30% | +24.5% |
| Vraylar | 12% | 12% | 11% | 12% | 12% | 12% | 12% | 13% | +19.0% |
| Botox Therapeutic | 12% | 12% | 13% | 12% | 12% | 12% | 13% | 12% | +12.3% |
| VENCLEXTA | 9% | 9% | 10% | 9% | 9% | 9% | 10% | 9% | +11.6% |
| HUMIRA | 31% | 22% | 17% | 15% | 13% | 15% | 9% | 9% | -35.9% |
| Botox Cosmetic | 9% | 9% | 8% | 9% | 8% | 9% | 9% | 9% | +5.2% |
| Other Products | 5% | 5% | 6% | 4% | 4% | 4% | 7% | 7% | +83.9% |
| Imbruvica | 10% | 10% | 10% | 8% | 8% | 7% | 6% | 5% | -33.0% |
| Ubrelvy | 4% | 4% | 4% | 4% | 4% | 4% | 5% | 5% | +16.0% |
| Qulipta | 2% | 3% | 3% | 3% | 4% | 3% | 4% | 4% | +31.1% |
| Other Aesthetics | 4% | 4% | 5% | 4% | 4% | 4% | 4% | 4% | -5.5% |
| Linzess Constella | 3% | 3% | 2% | 3% | 4% | 2% | 4% | 3% | +14.3% |
| MAVYRET | 4% | 4% | 5% | 5% | 4% | 4% | 5% | 3% | -21.3% |
| Vyalev | — | — | 1% | 1% | 2% | 2% | 3% | 3% | +161.2% |
| Juvederm Collection | 4% | 4% | 3% | 3% | 3% | 3% | 3% | 3% | -5.8% |
| Elahere | 1% | 4% | 3% | 2% | 2% | 2% | 3% | 2% | +32.7% |
| Creon | 2% | 3% | 3% | 3% | 2% | 2% | 2% | 2% | -14.6% |
| Other Neuroscience | 1% | 1% | 1% | 1% | 1% | 1% | 2% | 1% | +112.7% |
| Epkinly | <1% | <1% | <1% | 1% | 1% | 1% | 1% | 1% | +56.0% |
| Other Oncology | — | — | — | <1% | <1% | — | <1% | <1% | +1550.0% |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
Revenue by region
Q2 FY2026 · share of revenue
- US 72% ↓ 2 pt
- Non Us 20% ↑ 1 pt
As ABBV cuts its regions in its filings; they can nest, so they need not add to 100%.
Insider filings
64 filings between Feb 18, 2026 and Aug 14, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$18.92M
6 sales by 3 insiders
67% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 45
- Award — granted as compensation
- 4
- Option exercise — converted options into shares
- 9
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Siatis Perry C | — | $9.52M | Mar 2, 2026 |
| Donoghoe Nicholas | — | $8.18M | Aug 14, 2026 |
| Purdue David Ryan | — | $1.22M | Mar 4, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Aug 14, 2026 | Donoghoe Nicholas EVP, CHIEF BUS/STRAT OFFICER | Option exercise | 32,710 | $2.58M |
| Aug 14, 2026 | Donoghoe Nicholas EVP, CHIEF BUS/STRAT OFFICER | Sale | 32,710 | $8.18M |
| May 8, 2026 | Hart Brett J Director | Award | 1,118 | $0 |
| May 8, 2026 | Roberts Rebecca B Director | Award | 1,118 | $0 |
| May 8, 2026 | Quaggin Susan E Director | Award | 1,118 | $0 |
| May 8, 2026 | Davis Jennifer L. Director | Award | 1,118 | $0 |
| May 8, 2026 | MEYER MELODY B Director | Award | 1,118 | $0 |
| May 8, 2026 | FREYMAN THOMAS C Director | Award | 1,118 | $0 |
| May 8, 2026 | AUSTIN ROXANNE S Director | Award | 1,118 | $0 |
| May 8, 2026 | WADDELL FREDERICK H Director | Award | 1,118 | $0 |
| May 8, 2026 | FALK THOMAS J Director | Award | 1,118 | $0 |
| May 8, 2026 | RAPP EDWARD J Director | Award | 1,118 | $0 |
| May 8, 2026 | BURNSIDE WILLIAM H.L. Director | Award | 1,118 | $0 |
| Mar 4, 2026 | Purdue David Ryan SVP, Controller | Sale | 5,230 | $1.22M |
| Mar 2, 2026 | Siatis Perry C EVP, GC AND SECRETARY | Sale 10b5-1 plan | 2,600 | $611.7K |
| Mar 2, 2026 | Siatis Perry C EVP, GC AND SECRETARY | Sale 10b5-1 plan | 10,291 | $2.41M |
| Mar 2, 2026 | Siatis Perry C EVP, GC AND SECRETARY | Sale 10b5-1 plan | 5,777 | $1.35M |
| Feb 27, 2026 | Purdue David Ryan SVP, Controller | Tax withheld | 2,108 | $489.2K |
| Feb 27, 2026 | Crum Demetris D EVP, CHIEF HR OFFICER | Tax withheld | 1,594 | $369.9K |
| Feb 27, 2026 | SALEKI-GERHARDT AZITA EVP, CHIEF OPERATIONS OFFICER | Tax withheld | 16,309 | $3.78M |
| Feb 27, 2026 | Thakkar Roopal EVP, R&D and CSO | Tax withheld | 8,037 | $1.87M |
| Feb 27, 2026 | Reents Scott T EVP, CHIEF FINANCIAL OFFICER | Tax withheld | 21,638 | $5.02M |
| Feb 27, 2026 | Donoghoe Nicholas EVP, CHIEF BUS/STRAT OFFICER | Tax withheld | 12,874 | $2.99M |
| Feb 27, 2026 | Siatis Perry C EVP, GC AND SECRETARY | Tax withheld 10b5-1 plan | 14,850 | $3.45M |
| Feb 27, 2026 | Michael Robert A. CHAIRMAN OF THE BOARD AND CEO | Tax withheld | 36,523 | $8.48M |
| Feb 27, 2026 | Stewart Jeffrey Ryan EVP, CHIEF COMMERCIAL OFFICER | Tax withheld | 23,812 | $5.53M |
| Feb 25, 2026 | Siatis Perry C EVP, GC AND SECRETARY | Option exercise 10b5-1 plan | 7,292 | $1.41M |
| Feb 25, 2026 | Siatis Perry C EVP, GC AND SECRETARY | Option exercise 10b5-1 plan | 7,775 | $1.36M |
| Feb 25, 2026 | Siatis Perry C EVP, GC AND SECRETARY | Option exercise 10b5-1 plan | 7,314 | $1.09M |
| Feb 25, 2026 | Siatis Perry C EVP, GC AND SECRETARY | Sale 10b5-1 plan | 22,381 | $5.15M |
| Feb 18, 2026 | Reents Scott T EVP, CHIEF FINANCIAL OFFICER | Award | 7,260 | $0 |
| Feb 18, 2026 | Reents Scott T EVP, CHIEF FINANCIAL OFFICER | Award | 7,606 | $0 |
| Feb 18, 2026 | Reents Scott T EVP, CHIEF FINANCIAL OFFICER | Award | 8,910 | $0 |
| Feb 18, 2026 | Donoghoe Nicholas EVP, CHIEF BUS/STRAT OFFICER | Award | 6,222 | $0 |
| Feb 18, 2026 | Donoghoe Nicholas EVP, CHIEF BUS/STRAT OFFICER | Award | 5,172 | $0 |
| Feb 18, 2026 | Donoghoe Nicholas EVP, CHIEF BUS/STRAT OFFICER | Award | 4,632 | $0 |
| Feb 18, 2026 | Stewart Jeffrey Ryan EVP, CHIEF COMMERCIAL OFFICER | Award | 8,988 | $0 |
| Feb 18, 2026 | Stewart Jeffrey Ryan EVP, CHIEF COMMERCIAL OFFICER | Award | 9,432 | $0 |
| Feb 18, 2026 | Stewart Jeffrey Ryan EVP, CHIEF COMMERCIAL OFFICER | Award | 9,266 | $0 |
| Feb 18, 2026 | Stewart Jeffrey Ryan EVP, CHIEF COMMERCIAL OFFICER | Award | 26,063 | $0 |
| Feb 18, 2026 | Michael Robert A. CHIEF EXECUTIVE OFFICER | Award | 22,124 | $0 |
| Feb 18, 2026 | Donoghoe Nicholas EVP, CHIEF BUS/STRAT OFFICER | Award | 13,031 | $0 |
| Feb 18, 2026 | Michael Robert A. CHIEF EXECUTIVE OFFICER | Award | 14,452 | $0 |
| Feb 18, 2026 | Michael Robert A. CHIEF EXECUTIVE OFFICER | Award | 12,030 | $0 |
| Feb 18, 2026 | Michael Robert A. CHIEF EXECUTIVE OFFICER | Award | 33,833 | $0 |
| Feb 18, 2026 | Reents Scott T EVP, CHIEF FINANCIAL OFFICER | Award | 25,062 | $0 |
| Feb 18, 2026 | SALEKI-GERHARDT AZITA EVP, CHIEF OPERATIONS OFFICER | Award | 6,638 | $0 |
| Feb 18, 2026 | SALEKI-GERHARDT AZITA EVP, CHIEF OPERATIONS OFFICER | Award | 7,074 | $0 |
| Feb 18, 2026 | SALEKI-GERHARDT AZITA EVP, CHIEF OPERATIONS OFFICER | Award | 6,058 | $0 |
| Feb 18, 2026 | SALEKI-GERHARDT AZITA EVP, CHIEF OPERATIONS OFFICER | Award | 17,041 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for AbbVie Inc.
Free account. Everything above stays public.
Write why you follow AbbVie Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading
Other companies in Health Care
Nearest to AbbVie by market cap among the sector's top 20 companies at Q2 2026.